- Home
- TKNO vs EDIT Comparison
TKNO vs EDIT Comparison
Compare TKNO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKNO | EDIT |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.6M | 233.3M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TKNO | EDIT |
|---|---|---|
| Price | $4.65 | $2.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 200.9K | ★ 1.9M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $39,801,000.00 | ★ $46,383,000.00 |
| Revenue This Year | $9.52 | N/A |
| Revenue Next Year | $15.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.50 | N/A |
| 52 Week Low | $3.94 | $0.91 |
| 52 Week High | $10.37 | $4.54 |
Technical Indicators
Market Signals| Indicator | TKNO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 34.57 |
| Support Level | $4.25 | $2.33 |
| Resistance Level | $4.81 | $2.55 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 61.18 | 19.00 |
Price Performance
Historical ComparisonAbout TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.